ERYTHROPOIETIN

Stroke Disorder

Bundang CHA Hospitalprotein_peptidePhase 2Dormant

BB

64/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 95/ 100

Competitive context

128 Active assets in the Stroke Disorder cohort.

Asset / Sponsor	Phase	Rating
Aggrenox Boehringer Ingelheim	Phase 4	BBB
INCOBOTULINUMTOXINA Parc de Salut Mar	Phase 4	BBB
ATENOLOL Northern California Institute of Research and Education	Phase 4	BBB
Dextromethorphan University of Florida	Phase 4	BBB
Tenecteplase Assistance Publique - Hôpitaux de Paris	Phase 4	BBB

View all 50 →

Same molecule, other indications

ERYTHROPOIETIN is also rated in:

anemiaDormant

BBB

Indicative · Phase 4

78 / 100

disease related to hematopoietic stem cell transplantDormant

BB

Indicative · Phase 4

65 / 100

liver failureDormant

BB

Indicative · Phase 3

64 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.